These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9696398)

  • 21. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody.
    Weidner N; Moore DH; Vartanian R
    Hum Pathol; 1994 Apr; 25(4):337-42. PubMed ID: 8163266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer: does the antibody matter?
    Ács B; Kulka J; Kovács KA; Teleki I; Tőkés AM; Meczker Á; Győrffy B; Madaras L; Krenács T; Szász AM
    Hum Pathol; 2017 Jul; 65():31-40. PubMed ID: 28188752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences.
    Gaglia P; Bernardi A; Venesio T; Caldarola B; Lauro D; Cappa AP; Calderini P; Liscia DS
    Eur J Cancer; 1993; 29A(11):1509-13. PubMed ID: 8217353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Veronese SM; Maisano C; Scibilia J
    Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
    Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
    Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.
    Mu K; Li L; Yang Q; Yun H; Kharaziha P; Ye DW; Auer G; Lagercrantz SB; Zetterberg A
    Ann Diagn Pathol; 2015 Aug; 19(4):243-8. PubMed ID: 26049669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
    MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
    Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer.
    Goodson WH; Moore DH; Waldman FM
    J Clin Oncol; 2006 Aug; 24(23):3809; author reply 3809. PubMed ID: 16896010
    [No Abstract]   [Full Text] [Related]  

  • 31. Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.
    Molino A; Pedersini R; Micciolo R; Frisinghelli M; Giovannini M; Pavarana M; Nortilli R; Santo A; Manno P; Padovani M; Piubello Q; Cetto GL
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):304-9. PubMed ID: 12607597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.
    Langford LA; Cooksley CS; DeMonte F
    Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell proliferation in human tumour xenografts: measurement using antibody labelling against bromodeoxyuridine and Ki-67.
    Parkins CS; Bush C; Price P; Steel GG
    Cell Prolif; 1991 Mar; 24(2):171-9. PubMed ID: 2009320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
    Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro bromodeoxyuridine labeling of malignant neoplasms. A comparative study with flow cytometry cell-cycle analysis.
    Lloveras B; Garin-Chesa P; Myc A; Melamed M
    Am J Clin Pathol; 1994 Jun; 101(6):703-7. PubMed ID: 8209855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.
    Thakur SS; Li H; Chan AMY; Tudor R; Bigras G; Morris D; Enwere EK; Yang H
    PLoS One; 2018; 13(1):e0188983. PubMed ID: 29304138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
    McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
    J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MIB-1 proliferative activity in invasive breast cancer measured by image analysis.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Magri E; Indelli M; Nenci I
    J Clin Pathol; 1996 Nov; 49(11):926-30. PubMed ID: 8944614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.